EE200200357A - Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid - Google Patents
Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonidInfo
- Publication number
- EE200200357A EE200200357A EEP200200357A EEP200200357A EE200200357A EE 200200357 A EE200200357 A EE 200200357A EE P200200357 A EEP200200357 A EE P200200357A EE P200200357 A EEP200200357 A EE P200200357A EE 200200357 A EE200200357 A EE 200200357A
- Authority
- EE
- Estonia
- Prior art keywords
- pharmaceutical compositions
- drug substance
- providing increased
- increased concentrations
- compositions providing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17184199P | 1999-12-23 | 1999-12-23 | |
PCT/IB2000/001787 WO2001047495A1 (en) | 1999-12-23 | 2000-12-01 | Pharmaceutical compositions providing enhanced drug concentrations |
Publications (1)
Publication Number | Publication Date |
---|---|
EE200200357A true EE200200357A (et) | 2003-10-15 |
Family
ID=22625351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200200357A EE200200357A (et) | 1999-12-23 | 2000-12-01 | Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid |
Country Status (39)
Country | Link |
---|---|
US (6) | US8026286B2 (et) |
EP (3) | EP1239835B1 (et) |
JP (2) | JP2003518485A (et) |
KR (1) | KR100558239B1 (et) |
CN (1) | CN1402629A (et) |
AP (1) | AP2002002552A0 (et) |
AR (1) | AR027065A1 (et) |
AU (1) | AU784340B2 (et) |
BG (1) | BG106764A (et) |
BR (1) | BR0016555A (et) |
CA (1) | CA2395331C (et) |
CO (1) | CO5261563A1 (et) |
CR (1) | CR6654A (et) |
CZ (1) | CZ20022047A3 (et) |
DZ (1) | DZ3227A1 (et) |
EA (1) | EA006402B1 (et) |
EC (1) | ECSP003847A (et) |
EE (1) | EE200200357A (et) |
GE (1) | GEP20053427B (et) |
GT (1) | GT200000219A (et) |
HR (1) | HRP20020531A2 (et) |
HU (1) | HUP0204372A3 (et) |
IL (1) | IL149186A0 (et) |
IS (1) | IS6344A (et) |
MA (1) | MA26853A1 (et) |
MX (1) | MXPA02006324A (et) |
NO (1) | NO20022998L (et) |
OA (1) | OA12124A (et) |
PA (1) | PA8508701A1 (et) |
PE (1) | PE20010977A1 (et) |
PL (1) | PL357470A1 (et) |
SK (1) | SK8562002A3 (et) |
SV (1) | SV2002000248A (et) |
TN (1) | TNSN00252A1 (et) |
TR (1) | TR200201617T2 (et) |
UY (1) | UY26496A1 (et) |
WO (1) | WO2001047495A1 (et) |
YU (1) | YU43702A (et) |
ZA (1) | ZA200204962B (et) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
JP5767429B2 (ja) * | 1999-11-12 | 2015-08-19 | アッヴィ・インコーポレイテッド | 固体分散剤中の結晶化阻害剤 |
JP2003518485A (ja) * | 1999-12-23 | 2003-06-10 | ファイザー・プロダクツ・インク | 向上された薬物濃度を与える医薬組成物 |
UY26615A1 (es) | 2000-03-16 | 2001-10-25 | Pfizer Prod Inc | Inhibidor de la glucogeno fosforilasa. |
DE10026698A1 (de) * | 2000-05-30 | 2001-12-06 | Basf Ag | Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung |
US7674480B2 (en) * | 2000-06-23 | 2010-03-09 | Teva Pharmaceutical Industries Ltd. | Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition |
EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
EP1401399A2 (en) * | 2001-06-22 | 2004-03-31 | Pfizer Products Inc. | Pharmaceutical compositions containing polymer and drug assemblies |
US20030060422A1 (en) | 2001-08-31 | 2003-03-27 | Balaji Venkataraman | Tannate compositions and methods of treatment |
US7429238B2 (en) * | 2001-10-15 | 2008-09-30 | The Regents Of The University Of Michigan | Systems and methods for the generation of crystalline polymorphs |
EA008072B1 (ru) * | 2001-12-03 | 2007-02-27 | Новацея, Инк. | Фармацевтические составы, содержащие соединения активного витамина d |
IL162870A0 (en) | 2002-02-01 | 2005-11-20 | Pfizer Prod Inc | Controlled release pharmaceutical dosage forms of a cholesteryl estertransfer protein inhibitor |
EP1920766B1 (en) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
JP2005517690A (ja) * | 2002-02-01 | 2005-06-16 | ファイザー・プロダクツ・インク | 固体薬物分散物を含有する即時放出剤形 |
CA2474838C (en) | 2002-02-01 | 2009-01-06 | Pfizer Products Inc. | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
AU2003221535A1 (en) | 2002-03-28 | 2003-10-13 | Synthon B.V. | Venlafaxine besylate |
AU2003226752A1 (en) * | 2002-03-28 | 2003-10-13 | Synthon B.V. | Venlafaxine base |
US6696496B2 (en) | 2002-03-28 | 2004-02-24 | Synthon Bv | Low water-soluble venlafaxine salts |
DE60329188D1 (de) | 2002-08-12 | 2009-10-22 | Bend Res Inc | Arzneizubereitungen bestehend aus arzneimitteln in halb-geordneter form und polymeren |
EP1539157B1 (en) | 2002-09-18 | 2013-08-21 | Trustees Of The University Of Pennsylvania | Rapamycin for use in inhibiting or preventing choroidal neovascularization |
AU2002350719A1 (en) * | 2002-11-29 | 2004-06-23 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base |
US20050026877A1 (en) * | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
JP4542743B2 (ja) * | 2002-12-26 | 2010-09-15 | Kdl株式会社 | ピリドン誘導体の溶液状医薬組成物 |
NZ542097A (en) | 2003-04-29 | 2008-12-24 | Pfizer Ltd | 5,7-Diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension |
US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
WO2005004763A1 (en) * | 2003-07-01 | 2005-01-20 | Pharmacia & Upjohn Company Llc. | Diffusion layer modulated solids |
US20050048118A1 (en) * | 2003-07-25 | 2005-03-03 | Joan Cucala Escoi | Modified release venlafaxine hydrochloride tablets |
ATE540671T1 (de) * | 2003-08-04 | 2012-01-15 | Bend Res Inc | Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien |
US8377952B2 (en) * | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
BRPI0414082A (pt) * | 2003-09-02 | 2006-10-24 | Pfizer Prod Inc | formas de dosagem de liberação sustentada de ziprasidona |
US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
FR2861992B1 (fr) * | 2003-11-10 | 2007-07-20 | Sanofi Synthelabo | Composition pharmaceutique destinee a l'administration orale d'un derive de pyrazole-3-carboxamide. |
US7572799B2 (en) | 2003-11-24 | 2009-08-11 | Pfizer Inc | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
US20050112204A1 (en) * | 2003-11-25 | 2005-05-26 | Pfizer Inc. | Pharmaceutical formulations |
CA2552221A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
WO2005065657A2 (en) | 2003-12-31 | 2005-07-21 | Pfizer Products Inc. | Solid compositions of low-solubility drugs and poloxamers |
CA2552126A1 (en) * | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Ziprasidone formulations |
US8436029B2 (en) * | 2004-03-19 | 2013-05-07 | Transform Pharmaceuticals, Inc. | Pharmaceutical forms, and methods of making and using the same |
WO2005097799A1 (en) | 2004-04-07 | 2005-10-20 | Pfizer Limited | Pyrazolo`4,3-d! pyrimidines |
US8158138B1 (en) * | 2004-05-20 | 2012-04-17 | Fougera Pharmaceuticals, Inc. | Urea compositions and their methods of manufacture |
US7776358B2 (en) | 2004-07-22 | 2010-08-17 | Synthon Ip Inc. | Extended release venlafaxine besylate tablets |
CA2577852A1 (en) * | 2004-08-31 | 2006-03-09 | Pfizer Products Inc. | Pharmaceutical dosage forms comprising a low-solubility drug and a polymer |
EA014852B1 (ru) * | 2004-09-17 | 2011-02-28 | Дьюрект Корпорейшн | Система контролируемой доставки |
EP1844078B1 (en) | 2005-02-03 | 2016-09-28 | Bend Research, Inc | Pharmaceutical compositions with enhanced performance |
KR101387456B1 (ko) | 2005-02-09 | 2014-04-21 | 산텐 세이야꾸 가부시키가이샤 | 질환 또는 상태의 치료를 위한 액체 제제 |
US20070287719A1 (en) * | 2005-03-11 | 2007-12-13 | Pfizer Inc | Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea |
WO2007014393A2 (en) * | 2005-07-28 | 2007-02-01 | Isp Investments Inc. | Amorphous efavirenz and the production thereof |
EP2001438A2 (en) | 2006-02-09 | 2008-12-17 | Macusight, Inc. | Stable formulations, and methods of their preparation and use |
DK2001466T3 (en) | 2006-03-23 | 2016-02-29 | Santen Pharmaceutical Co Ltd | LOW-DOSAGE RAPAMYCINE FOR TREATMENT OF VASCULAR PERMEABILITY-RELATED DISEASES |
US8900619B2 (en) | 2006-08-24 | 2014-12-02 | Boston Scientific Scimed, Inc. | Medical devices for the release of therapeutic agents |
US20100029743A1 (en) * | 2006-09-27 | 2010-02-04 | Dr. Reddy's Laboratories Ltd. | Atorvastatin pharmaceutical compositions |
US20080085315A1 (en) * | 2006-10-10 | 2008-04-10 | John Alfred Doney | Amorphous ezetimibe and the production thereof |
EP1920767A1 (en) * | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
US20080152717A1 (en) * | 2006-12-14 | 2008-06-26 | Isp Investments, Inc. | Amorphous valsartan and the production thereof |
WO2008080037A2 (en) * | 2006-12-21 | 2008-07-03 | Isp Investments Inc. | Carotenoids of enhanced bioavailability |
JP5508859B2 (ja) * | 2007-01-26 | 2014-06-04 | アイエスピー インヴェストメンツ インコーポレイテッド | 噴霧乾燥製品を製造するための調剤処理方法 |
US20080181961A1 (en) * | 2007-01-26 | 2008-07-31 | Isp Investments, Inc. | Amorphous oxcarbazepine and the production thereof |
WO2009010837A2 (en) * | 2007-07-13 | 2009-01-22 | Pfizer Products Inc. | Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer |
US20090203709A1 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor |
EP2257220B1 (en) * | 2008-03-13 | 2017-06-14 | Liebel-Flarsheim Company LLC | Multi-function, foot-activated controller for imaging system |
US20100048912A1 (en) | 2008-03-14 | 2010-02-25 | Angela Brodie | Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
US20110312916A1 (en) | 2009-02-05 | 2011-12-22 | Tokai Pharmaceuticals, Inc. | Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
AU2010260208B2 (en) | 2009-06-16 | 2014-11-13 | Bristol-Myers Squibb Holdings Ireland Unlimited Company | Dosage forms of apixaban |
WO2011068403A2 (en) | 2009-12-02 | 2011-06-09 | Ultimorphix Technologies B.V. | Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts |
US8921337B2 (en) | 2009-12-03 | 2014-12-30 | Alcon Research, Ltd. | Carboxyvinyl polymer-containing nanoparticle suspensions |
WO2011148253A2 (en) | 2010-05-25 | 2011-12-01 | Aurobindo Pharma Limited | Solid dosage forms of antipsychotics |
US20120015913A1 (en) * | 2010-07-15 | 2012-01-19 | Delansorne Remi | Formulations of 14-EPI-Analogues of Vitamin D |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
JP5913367B2 (ja) | 2011-01-05 | 2016-04-27 | ホスピーラ インコーポレイテッド | バンコマイシンの噴霧乾燥 |
US8591944B2 (en) | 2011-03-08 | 2013-11-26 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
TWI544922B (zh) | 2011-05-19 | 2016-08-11 | 愛爾康研究有限公司 | 高濃度歐羅派特錠(olopatadine)眼用組成物 |
US9119793B1 (en) | 2011-06-28 | 2015-09-01 | Medicis Pharmaceutical Corporation | Gastroretentive dosage forms for doxycycline |
JP5879803B2 (ja) * | 2011-08-08 | 2016-03-08 | ライオン株式会社 | 固形医薬組成物、その製造方法及び医薬製剤 |
KR102123130B1 (ko) | 2012-05-31 | 2020-06-15 | 머크 샤프 앤드 돔 코포레이션 | 오렉신 수용체 길항제의 고체 투여 제제 |
CN104736142B (zh) | 2012-09-26 | 2020-03-03 | 百时美-施贵宝控股爱尔兰无限公司 | 阿哌沙班液体制剂 |
CN104853752B (zh) | 2012-10-18 | 2018-10-23 | 艾伯维公司 | 嘧啶二酮衍生物化合物的制剂 |
WO2014133885A1 (en) | 2013-03-01 | 2014-09-04 | Hercules Incorporated | Pharmaceutical compositions with enhanced performance and improved processability |
SG11201507093WA (en) | 2013-03-14 | 2015-10-29 | Univ Maryland Baltimore Office Of Technology Transfer | Androgen receptor down-regulating agents and uses thereof |
CN104043104B (zh) | 2013-03-15 | 2018-07-10 | 浙江创新生物有限公司 | 含盐酸万古霉素的喷雾干粉及其工业化制备方法 |
US10842802B2 (en) | 2013-03-15 | 2020-11-24 | Medicis Pharmaceutical Corporation | Controlled release pharmaceutical dosage forms |
EP3027171B1 (en) * | 2013-07-30 | 2020-03-25 | Gilead Connecticut, Inc. | Formulation of syk inhibitors |
RU2016104643A (ru) | 2013-08-12 | 2017-09-19 | Токай Фармасьютикалз, Инк. | Биомаркёры для лечения неопластических заболеваний с применением нацеленных на андроген методов лечения |
UY35898A (es) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
TW201613579A (en) | 2014-06-24 | 2016-04-16 | Astellas Pharma Inc | Pharmaceutical composition for oral administration |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
EP3340982B1 (en) | 2015-08-26 | 2021-12-15 | Achillion Pharmaceuticals, Inc. | Compounds for treatment of immune and inflammatory disorders |
AR106018A1 (es) | 2015-08-26 | 2017-12-06 | Achillion Pharmaceuticals Inc | Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos |
EP3442524A2 (en) | 2016-04-15 | 2019-02-20 | Novira Therapeutics Inc. | Combinations and methods comprising a capsid assembly inhibitor |
GB201609222D0 (en) | 2016-05-25 | 2016-07-06 | F2G Ltd | Pharmaceutical formulation |
AU2017290593A1 (en) | 2016-06-27 | 2019-01-03 | Achillion Pharmaceuticals, Inc. | Quinazoline and indole compounds to treat medical disorders |
JP2020503269A (ja) | 2016-11-28 | 2020-01-30 | リポカイン インコーポレーテッド | 経口ウンデカン酸テストステロン療法 |
KR102117677B1 (ko) * | 2018-03-08 | 2020-06-01 | (주)이엘티사이언스 | 용해도가 개선된 축산용 삼종염 소독제 복합조성물 |
US10973801B2 (en) | 2018-03-14 | 2021-04-13 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
JP7244536B2 (ja) | 2018-04-06 | 2023-03-22 | キャプシュゲル・ベルジウム・エヌ・ヴィ | メタクリル酸メチル-メタクリル酸コポリマーからなる低アスペクト比の粒子のための噴霧乾燥方法 |
JP7333340B2 (ja) * | 2018-05-14 | 2023-08-24 | キャプシュゲル・ベルジウム・エヌ・ヴィ | 高い活性薬剤ローディングを有する固体剤形 |
CN112955134A (zh) | 2018-07-19 | 2021-06-11 | 英倍尔药业股份有限公司 | 用于治疗帕金森氏病的左旋多巴和多巴脱羧酶抑制剂的呼吸道递送 |
JP2021535112A (ja) | 2018-08-20 | 2021-12-16 | アキリオン ファーマシューティカルズ,インコーポレーテッド | 補体d因子の医学的障害の治療のための医薬化合物 |
EP3866773A4 (en) | 2018-10-16 | 2022-10-26 | Georgia State University Research Foundation, Inc. | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL CONDITIONS |
KR20210131372A (ko) | 2019-02-22 | 2021-11-02 | 크로노스 바이오, 인코포레이티드 | Syk 억제제로서의 축합된 피라진의 고체 형태 |
US11819503B2 (en) | 2019-04-23 | 2023-11-21 | F2G Ltd | Method of treating coccidioides infection |
JP7188364B2 (ja) * | 2019-11-25 | 2022-12-13 | トヨタ自動車株式会社 | 車椅子乗客拘束構造 |
CN115666621A (zh) | 2020-01-13 | 2023-01-31 | 度勒科特公司 | 具有减少的杂质的持续释放药物递送***及相关方法 |
WO2024012361A1 (zh) * | 2022-07-11 | 2024-01-18 | 江苏恩华药业股份有限公司 | 阿法沙龙脂肪乳注射液及其制备方法 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4344934A (en) | 1978-11-20 | 1982-08-17 | American Home Products Corporation | Therapeutic compositions with enhanced bioavailability |
CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
US4301146A (en) | 1980-07-29 | 1981-11-17 | G. D. Searle & Co. | Stabilization of 16-oxygenated prostanoic acid derivatives |
US4321253A (en) | 1980-08-22 | 1982-03-23 | Beatty Morgan L | Suspension of microencapsulated bacampicillin acid addition salt for oral, especially pediatric, administration |
DE3224619A1 (de) | 1981-07-14 | 1983-05-19 | Freund Industrial Co., Ltd., Tokyo | Orale pharmazeutische zusammensetzung |
FR2525108B1 (fr) | 1982-04-19 | 1989-05-12 | Elan Corp Ltd | Medicaments a haut degre de solubilite et procede pour leur obtention |
US4461759A (en) * | 1983-01-03 | 1984-07-24 | Verex Laboratories, Inc. | Constant release rate solid oral dosage formulations of veropamil |
US4933360A (en) | 1983-03-16 | 1990-06-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel chlorthalidone process and product |
US4517179A (en) | 1983-04-29 | 1985-05-14 | Pennwalt Corporation | Rapid dissolving, uniform drug compositions and their preparation |
DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
IT1187751B (it) | 1985-10-15 | 1987-12-23 | Eurand Spa | Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute |
IE63321B1 (en) | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
JPS6314724A (ja) | 1986-07-08 | 1988-01-21 | Tooa Eiyoo Kk | プラゾシン製剤 |
DE3877331T2 (de) | 1987-11-11 | 1993-05-27 | Pharmascience Lab | Exifon und ein wasserloesliches polymer enthaltende pharmazeutische zubereitung. |
IE60383B1 (en) | 1988-05-27 | 1994-07-13 | Elan Corp Plc | Controlled release pharmaceutical formulation |
JP2528706B2 (ja) * | 1988-05-30 | 1996-08-28 | ゼリア新薬工業株式会社 | ジヒドロピリジン化合物の製剤組成物 |
US5368864A (en) | 1988-11-25 | 1994-11-29 | Henning Berlin Gmbh Chemie- Und Pharmawerk | Formulation of oxypurinol and/or its alkali and alkaline earth salts |
JPH02149518A (ja) | 1988-11-30 | 1990-06-08 | Nikken Chem Co Ltd | 経口投与用薬剤 |
IL92966A (en) * | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
CA2020654A1 (en) * | 1989-07-07 | 1991-01-08 | Yohko Akiyama | Stabilized fgf composition and production thereof |
US5035897A (en) | 1989-09-05 | 1991-07-30 | Alza Corporation | Dosage form for delivering soluble or insoluble drugs |
JP2939491B2 (ja) * | 1989-12-11 | 1999-08-25 | 株式会社アドバンス | 機能性食品 |
JP2558396B2 (ja) | 1990-06-28 | 1996-11-27 | 田辺製薬株式会社 | 放出制御型製剤 |
WO1992001453A1 (en) | 1990-07-19 | 1992-02-06 | Otsuka Pharmaceutical Co., Ltd. | Solid preparation |
US5292520A (en) | 1990-09-13 | 1994-03-08 | Akzo N.V. | Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer |
US5102668A (en) * | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
EP0482948A1 (en) | 1990-10-26 | 1992-04-29 | Asahi Kasei Kogyo Kabushiki Kaisha | A medicament composition containing 6-substituted alkoxy quinoxaline derivative and its production |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
EP0580860B2 (en) | 1991-04-16 | 2004-12-15 | Nippon Shinyaku Company, Limited | Method of manufacturing solid dispersion |
HU222501B1 (hu) | 1991-06-28 | 2003-07-28 | Endorecherche Inc. | MPA-t vagy MGA-t tartalmazó nyújtott hatóanyag-felszabadulású gyógyászati készítmény és eljárás előállítására |
JP2881519B2 (ja) | 1991-07-09 | 1999-04-12 | 中塚工業 株式会社 | 艶消し立体模様箔糸原反の製造法 |
US5225204A (en) | 1991-11-05 | 1993-07-06 | Chen Jivn Ren | Stable dosage of levothyroxine sodium and process of production |
DK89592D0 (da) | 1992-07-07 | 1992-07-07 | Helle Broendsted | Laegemiddelafgivelsesindretning samt fremgangsmaade til fremstilling deraf |
US5811547A (en) | 1992-10-14 | 1998-09-22 | Nippon Shinyaju Co., Ltd. | Method for inducing crystalline state transition in medicinal substance |
JPH06128147A (ja) * | 1992-10-20 | 1994-05-10 | Masayasu Sugihara | 水難溶性薬品の溶解性改善方法およびそれにより得られた薬品組成物 |
JPH06314724A (ja) | 1993-04-28 | 1994-11-08 | Hitachi Cable Ltd | 半導体素子搭載用両面配線基板,及びそれを用いた半導 体装置 |
JP2916978B2 (ja) * | 1993-08-25 | 1999-07-05 | エスエス製薬株式会社 | 放出開始制御型製剤 |
US5773025A (en) | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
US5972383A (en) | 1994-03-02 | 1999-10-26 | Eli Lilly And Company | Solid orally administerable raloxifene hydrochloride pharmaceutical formulation |
TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
WO1996019239A1 (fr) | 1994-12-21 | 1996-06-27 | Yamanouchi Pharmaceutical Co., Ltd. | Composition solide a solubilite et absorbabilite ameliorees |
US5716642A (en) | 1995-01-10 | 1998-02-10 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents |
US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5573783A (en) | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
ATE306903T1 (de) * | 1995-03-24 | 2005-11-15 | Genzyme Corp | Verminderung von adhäsionen durch gesteuerte verabreichung von aktivsauerstoffinhibitoren |
US5654005A (en) * | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
WO1997004782A1 (fr) | 1995-07-26 | 1997-02-13 | Kyowa Hakko Kogyo Co., Ltd. | Dispersion solide ou preparation a dispersion solide de derives xanthine |
GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
TW487582B (en) * | 1995-08-11 | 2002-05-21 | Nissan Chemical Ind Ltd | Method for converting sparingly water-soluble medical substance to amorphous state |
DE19531684A1 (de) | 1995-08-29 | 1997-03-06 | Bayer Ag | Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung |
GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
JPH09309828A (ja) | 1996-03-18 | 1997-12-02 | Eisai Co Ltd | 溶解を改善した薬剤組成物 |
HU229057B1 (en) * | 1996-05-07 | 2013-07-29 | Pfizer | Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist |
JPH107558A (ja) | 1996-06-19 | 1998-01-13 | Eisai Co Ltd | 溶解性改善製剤 |
EP0826685A1 (en) * | 1996-08-21 | 1998-03-04 | Pfizer Inc. | Stable, long acting salts of carboxamides for the treatment of joint disease |
ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
US5977158A (en) | 1996-11-28 | 1999-11-02 | Novo Nordisk A/S | Pharmaceutical formulations comprising levormeloxifene compounds |
WO1999001120A1 (en) | 1997-07-01 | 1999-01-14 | Pfizer Products Inc. | Solubilized sertraline compositions |
DK0901786T3 (da) * | 1997-08-11 | 2007-10-08 | Pfizer Prod Inc | Faste farmaceutiske dispersioner med foröget biotilgængelighed |
HN1998000115A (es) | 1997-08-21 | 1999-06-02 | Warner Lambert Co | Formas de dosificación farmacéuticas sólidas |
CA2273272C (en) * | 1997-10-07 | 2004-09-21 | Fuisz Technologies Ltd. | Immediate release drug delivery forms |
US6110502A (en) * | 1998-02-19 | 2000-08-29 | Mcneil-Ppc, Inc. | Method for producing water dispersible sterol formulations |
CA2328703C (en) | 1998-06-11 | 2007-10-30 | Pharmacia & Upjohn Company | Delavirdine tablet formulation |
ES2157731B1 (es) | 1998-07-21 | 2002-05-01 | Liconsa Liberacion Controlada | Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion. |
WO2000018374A1 (en) | 1998-10-01 | 2000-04-06 | Elan Pharma International, Ltd. | Controlled release nanoparticulate compositions |
ES2306646T3 (es) * | 1999-02-09 | 2008-11-16 | Pfizer Products Inc. | Composiciones de farmacos basicos con biodisponibilidad incrementada. |
ES2307482T3 (es) | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
ATE404178T1 (de) * | 1999-02-10 | 2008-08-15 | Pfizer Prod Inc | Vorrichtung mit matrixgesteuerter wirkstofffreisetzung |
DE60042352D1 (de) | 1999-02-10 | 2009-07-23 | Pfizer Prod Inc | Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
KR100645866B1 (ko) | 1999-12-08 | 2006-11-15 | 파마시아 코포레이션 | 발데콕시브 조성물 |
CN1376146B (zh) | 1999-12-08 | 2011-04-06 | 法马西亚公司 | 提高了生物利用率的雪列柯西的固态形式 |
JP2003518485A (ja) * | 1999-12-23 | 2003-06-10 | ファイザー・プロダクツ・インク | 向上された薬物濃度を与える医薬組成物 |
US20010053778A1 (en) * | 2000-03-16 | 2001-12-20 | Hoover Dennis J. | Pharmaceutical compositions of glycogen phosphorylase inhibitors |
-
2000
- 2000-12-01 JP JP2001548090A patent/JP2003518485A/ja active Pending
- 2000-12-01 TR TR2002/01617T patent/TR200201617T2/xx unknown
- 2000-12-01 EE EEP200200357A patent/EE200200357A/et unknown
- 2000-12-01 MX MXPA02006324A patent/MXPA02006324A/es active IP Right Grant
- 2000-12-01 GE GE4831A patent/GEP20053427B/en unknown
- 2000-12-01 IL IL14918600A patent/IL149186A0/xx unknown
- 2000-12-01 BR BR0016555-7A patent/BR0016555A/pt not_active Application Discontinuation
- 2000-12-01 EP EP00976217A patent/EP1239835B1/en not_active Expired - Lifetime
- 2000-12-01 EA EA200200431A patent/EA006402B1/ru not_active IP Right Cessation
- 2000-12-01 YU YU43702A patent/YU43702A/sh unknown
- 2000-12-01 PL PL00357470A patent/PL357470A1/xx not_active Application Discontinuation
- 2000-12-01 WO PCT/IB2000/001787 patent/WO2001047495A1/en not_active Application Discontinuation
- 2000-12-01 CA CA002395331A patent/CA2395331C/en not_active Expired - Fee Related
- 2000-12-01 OA OA1200200191A patent/OA12124A/en unknown
- 2000-12-01 CZ CZ20022047A patent/CZ20022047A3/cs unknown
- 2000-12-01 EP EP06117015A patent/EP1712222A3/en not_active Withdrawn
- 2000-12-01 CN CN00816563A patent/CN1402629A/zh active Pending
- 2000-12-01 SK SK856-2002A patent/SK8562002A3/sk unknown
- 2000-12-01 HU HU0204372A patent/HUP0204372A3/hu unknown
- 2000-12-01 AP APAP/P/2002/002552A patent/AP2002002552A0/en unknown
- 2000-12-01 KR KR1020027008138A patent/KR100558239B1/ko not_active IP Right Cessation
- 2000-12-01 DZ DZ003227A patent/DZ3227A1/fr active
- 2000-12-01 EP EP06117018A patent/EP1738749A1/en not_active Ceased
- 2000-12-01 AU AU14091/01A patent/AU784340B2/en not_active Ceased
- 2000-12-13 PA PA20008508701A patent/PA8508701A1/es unknown
- 2000-12-14 CO CO00095393A patent/CO5261563A1/es not_active Application Discontinuation
- 2000-12-20 US US09/742,785 patent/US8026286B2/en not_active Expired - Fee Related
- 2000-12-20 UY UY26496A patent/UY26496A1/es not_active Application Discontinuation
- 2000-12-21 PE PE2000001384A patent/PE20010977A1/es not_active Application Discontinuation
- 2000-12-21 EC EC2000003847A patent/ECSP003847A/es unknown
- 2000-12-21 GT GT200000219A patent/GT200000219A/es unknown
- 2000-12-21 AR ARP000106852A patent/AR027065A1/es unknown
- 2000-12-22 TN TNTNSN00252A patent/TNSN00252A1/fr unknown
- 2000-12-22 SV SV2000000248A patent/SV2002000248A/es unknown
-
2002
- 2002-04-16 IS IS6344A patent/IS6344A/is unknown
- 2002-05-31 BG BG106764A patent/BG106764A/bg unknown
- 2002-06-04 CR CR6654A patent/CR6654A/es not_active Application Discontinuation
- 2002-06-13 MA MA26687A patent/MA26853A1/fr unknown
- 2002-06-18 HR HR20020531A patent/HRP20020531A2/hr not_active Application Discontinuation
- 2002-06-20 ZA ZA200204962A patent/ZA200204962B/en unknown
- 2002-06-21 NO NO20022998A patent/NO20022998L/no not_active Application Discontinuation
-
2007
- 2007-11-01 JP JP2007285190A patent/JP2008101004A/ja not_active Withdrawn
-
2011
- 2011-08-11 US US13/208,305 patent/US8202912B2/en not_active Expired - Lifetime
-
2012
- 2012-06-19 US US13/527,536 patent/US8501231B2/en not_active Expired - Fee Related
-
2013
- 2013-06-11 US US13/915,311 patent/US8796341B2/en not_active Expired - Fee Related
-
2014
- 2014-07-14 US US14/331,172 patent/US8980321B2/en not_active Expired - Fee Related
-
2015
- 2015-03-16 US US14/659,271 patent/US9457095B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200200357A (et) | Ravimaine suurenenud kontsentratsioone andvad farmatseutilised kompositsioonid | |
NO20022970D0 (no) | Hydrogel-drevet medikamentdoseringsform | |
PT1221918E (pt) | Administracao de drogas sub-tenon | |
NO20020464L (no) | Flerkomponents farmasöytisk doseringsform | |
NO20015175D0 (no) | Farmasöytisk sammensetning | |
FR2795324B1 (fr) | Compositions pharmaceutiques stabilisees | |
NO20006630D0 (no) | Farmasöytisk sammensetning for behandlingen av diabetes | |
ITTO20010008A0 (it) | Formulazione farmaceutica | |
FI991485A (fi) | Uusi farmaseuttinen koostumus | |
PT1242087E (pt) | Composicoes farmaceuticas | |
NO20020086L (no) | Smaksmaskerte farmasöytiske flytende formuleringer | |
ATE317260T1 (de) | Pharmazeutische formulierungen mit platinderivaten | |
ATE307571T1 (de) | Pharmazeutische formulierung enthaltend bicalutamid | |
EE04418B1 (et) | Moksifloksatsiini farmatseutiline preparaat | |
EE05020B1 (et) | Glburiidi ravimkoostis | |
NO20015670D0 (no) | Forbedrede farmasöytiske formuleringer | |
ATE383868T1 (de) | Pharmazeutische formulierung enthaltend megalatran und dessen pro-pharmaka | |
FR2802423B1 (fr) | Compositions pharmaceutiques | |
NO20014926D0 (no) | Farmasöytiske forbindelser | |
NO20021898D0 (no) | Farmasöytisk sammensetning inneholdende ciclesonid for applikasjon til mukosa | |
EE200300135A (et) | Trüptamiini derivaadid ja analoogsed ühendid ningneid sisaldavad farmatseutilised preparaadid | |
ID30032A (id) | Formulasi farmasi | |
PT1227817E (pt) | Composicao farmaceutica aquosa contendo ciclesonida | |
FI4488U1 (fi) | Farmaseuttinen koostumus | |
AR025867A1 (es) | Formulacion portasdora farmaceutica |